Paritaprevir

帕利普韦

Report date: 2023/05/01 20:00:20
NME

Base Information

Drug NameParitaprevir
Drug Alias Name帕利瑞韦paritaprevirparitaprevirumVeruprevirVeruprevir anhydrous +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHepatitis C virus serine protease, NS3/NS4A inhibitors
TargetsHepatitis C virus serine protease, NS3/NS4A
Therapy Area/IndicationsHepatitis C, ChronicHepatitis C
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesEgypt
CombinationsNo
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesEnanta Pharmaceuticals IncAbbott Laboratories
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAbbott LaboratoriesBeni Suef UniversityAbbvie Inc +[4] 
Active IndicationsN/A
Inactive IndicationsHepatitis C, ChronicHepatitis C

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG